Literature DB >> 11921315

Is there a kink in consumers' threshold value for cost-effectiveness in health care?

Bernie J O'Brien1, Kirsten Gertsen, Andrew R Willan, Lisa A Faulkner.   

Abstract

BACKGROUND: A reproducible observation is that consumers' willingness-to-accept (WTA) monetary compensation to forgo a program is greater than their stated willingness-to-pay (WTP) for the same benefit. Several explanations exist, including the psychological principle that the utility of losses weighs heavier than gains. We sought to quantify the WTP-WTA disparity from published literature and explore implications for cost-effectiveness analysis accept-reject thresholds in the south-west quadrant of the cost-effectiveness plane (less effect, less cost).
METHODS: We reviewed published studies (health and non-health) to estimate the ratio of WTA to WTP for the same program benefit for each study and to determine if WTA is consistently greater than WTP in the literature.
RESULTS: WTA/WTP ratios were greater than unity for every study we reviewed. The ratios ranged from 3.2 to 89.4 for environmental studies (n=7), 1.9 to 6.4 for health care studies (n=2), 1.1 to 3.6 for safety studies (n=4) and 1.3 to 2.6 for experimental studies (n=7).
CONCLUSIONS: Given that WTA is greater than WTP based on individual preferences, should not societal preferences used to determine cost-effectiveness thresholds reflect this disparity? Current convention in cost-effectiveness analysis is that any given accept-rejection criterion (e.g. $50 k/QALY gained) is symmetric - a straight line through the origin of the cost-effectiveness plane. The WTA-WTP evidence suggests a downward 'kink' through the origin for the south-west quadrant, such that the 'selling price' of a QALY is greater than the 'buying price'. The possibility of 'kinky cost-effectiveness' decision rules and the size of the kink merits further exploration. Copyright 2002 John Wiley & Sons, Ltd.

Mesh:

Year:  2002        PMID: 11921315     DOI: 10.1002/hec.655

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  38 in total

1.  Cost-effectiveness of multimodal CT for evaluating acute stroke.

Authors:  Kate C Young; Curtis G Benesch; Babak S Jahromi
Journal:  Neurology       Date:  2010-10-06       Impact factor: 9.910

2.  Discounting health effects in pharmacoeconomic evaluations: current controversies.

Authors:  J M Bos; Maarten J Postma; Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  No room for kinkiness in a public healthcare system.

Authors:  Jack Dowie
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Economic evaluation and decision making in the UK.

Authors:  Martin J Buxton
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 5.  Estimation, power and sample size calculations for stochastic cost and effectiveness analysis.

Authors:  S D Walter; Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 6.  Bias in published cost effectiveness studies: systematic review.

Authors:  Chaim M Bell; David R Urbach; Joel G Ray; Ahmed Bayoumi; Allison B Rosen; Dan Greenberg; Peter J Neumann
Journal:  BMJ       Date:  2006-02-22

7.  Loss aversion and cost effectiveness of healthcare programmes.

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  Loss aversion and cost effectiveness of healthcare programmes: whose aversion counts anyway?

Authors:  Johan L Severens; J L Hans Severens
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits?

Authors:  Kathryn A Phillips; Deborah A Marshall; Allison W Kurian
Journal:  Per Med       Date:  2019-09-25       Impact factor: 2.512

10.  Differences between willingness to pay and willingness to accept for visits by a family physician: a contingent valuation study.

Authors:  Jesús Martín-Fernández; Ma Isabel del Cura-González; Tomás Gómez-Gascón; Juan Oliva-Moreno; Julia Domínguez-Bidagor; Milagros Beamud-Lagos; Francisco Javier Pérez-Rivas
Journal:  BMC Public Health       Date:  2010-05-10       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.